• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.16% Nasdaq Up0.25%

    CEL-SCI Corporation (CVM)

    -NYSE MKT
    0.75 Up 0.01(0.74%) Jun 1, 4:00PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    CEL-SCI Corporation
    8229 Boone Boulevard
    Suite 802
    Vienna, VA 22182
    United States - Map
    Phone: 703-506-9460
    Fax: 703-506-9471
    Website: http://www.cel-sci.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:N/A

    Business Summary 

    CEL-SCI Corporation engages in the research and development of drugs and vaccines. The company’s lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. Multikine is also being used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System (LEAPS), a patented T-cell modulation process, stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune, allergies, transplantation rejection, and cancer. The company, through its LEAPS technology, provides peptide treatment for H1N1 hospitalized patients; and CEL-2000, a rheumatoid arthritis vaccine. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on CEL-SCI Corporation

    Key Executives 
     PayExercised
    Mr. Maximilian De Clara , 85
    Founder, Chairman and Pres
    765.00K0.00
    Mr. Geert R. Kersten Esq., 56
    Chief Exec. Officer, Treasurer and Director
    725.00K0.00
    Ms. Patricia B. Prichep , 64
    Sr. VP of Operations and Corp. Sec.
    254.00K0.00
    Dr. Eyal Talor Ph.D., 59
    Chief Scientific Officer
    289.00K0.00
    Dr. Daniel H. Zimmerman Ph.D., 74
    Sr. VP of Research - Cellular Immunology
    219.00K0.00
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders